No harm to brain function from Zebinix/Aptiom, data shows

23 June 2017

Portuguese pharma firm BIAL and Japan’s Eisai (TYO: 4523) have announced data from a Phase II study which showed that treatment with Zebinix (eslicarbazepine acetate) had no significant negative impact on attention, information processing and working memory in children with focal-onset epilepsy.

Given that it is well-documented that some anti-epileptic drugs (AEDs) may contribute to negative effects on cognition in epilepsy, this data, being presented on Friday at the EPNS (European Pediatric Neurology Society) congress, could represent an important step forward.

Study 208 evaluated the effect of eslicarbazepine acetate on power of attention in children aged six to 16 years with focal epilepsy, versus placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK